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Objective To investigate whether chronic obstructive pulmonary disease (COPD) 
screening that combines screening with questionnaires and pulmonary function testing 
is a useful method for the early detection of COPD. 
 
Methods A total of 3,367 subjects over 50 years of age underwent COPD screening. 
Two thousand five hundred and seventy-two of these subjects underwent“Ningen Dock” 
(a Japanese-English term for annual health checkup) examinations, regularly-scheduled 
check-ups or screenings in outpatient clinics. Of these subjects, 795 lived in one city 
and one town in Nagasaki Prefecture and exhibited a score of at least 5 points on the 
Eleven-item pre-interview questionnaire (11-Q). The prevalence of airflow limitation in 
each type of examination was calculated for each gender, and the odds ratios of airflow 
limitation with each type of examination were obtained using the subjects who 
underwent “Ningen Dock” examinations as the reference group. 
 
Results The COPD prevalence was 6.5% in the “Ningen Dock” group (7.9% men, 1.8% 
women), 5.8% in the regularly-scheduled checkup group (7.4% men, 4.1% women), 
9.8% in the screening in outpatient clinics group (12.1% men, 7.2% women) and 22.3% 
in the COPD screening group (31.1% men, 8.1% women), with the COPD screening 
group showing the highest prevalence. The odds ratios of the COPD prevalence 
confirmed that COPD screening is more effective for identifying airflow limitation than 





Conclusions Conducting COPD screening with questionnaires and pulmonary function 
testing among the general population is a useful examination method for the early 
detection and treatment of COPD. 
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  The incidence of chronic obstructive pulmonary disease (COPD) is increasing 
worldwide. COPD is estimated to become the 3rd leading global cause of death by 2020 
(1) and is of major economic concern. However, COPD is preventable and treatable; 
therefore, the importance of early detection and treatment has been emphasized (2). 
Many epidemiological studies have been conducted to determine the prevalence of 
COPD (3-5). In Japan, a large-scale epidemiological study that utilized a questionnaire 
(the Nippon COPD Epidemiology [NICE] study) (6) reported that 10.6% of the subjects 
exhibited airflow limitation and at least 8.6% were thought to have COPD, thus 
suggesting that the prevalence of COPD in Japan is similar to that observed in other 
foreign countries. 
  COPD epidemiology research has been conducted in various populations such as 
outpatients, the general public and people who undergo health examinations. In a British 
health survey of the general public, the prevalence of COPD was 13.3% (7). The 
prevalence of COPD in workers commuting to a health prevention center was 7.5% in a 
study by Roche et al. (8). In a study by Yawn et al. (9) of an outpatient population, the 
prevalence of COPD was 26%. In Japan, the prevalence of COPD among outpatients 
was 10.3% in a study by Minakata et al. (10), while the prevalence of COPD at 
regularly-scheduled check-ups was 7.0% in a study by Omori et al. (11). 
Because the implementation rate of pulmonary function testing, which is essential for 
the diagnosis of COPD, is low, questionnaires based on symptoms have been developed 
to screen outpatients for the early detection of COPD. Sichletidis et al. (12) proposed 
that the combined use of pulmonary function testing and an International Primary Care 
Airways Guidelines (IPAG) questionnaire is useful for the early diagnosis of COPD. 
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Kida et al. (13) also reported that the Eleven-item pre-interview questionnaire (11-Q) is 
useful for predicting COPD.  
  Various types of examinations have been used for the early detection of COPD, 
resulting in different prevalence rates. It is unknown which type of examination is most 
effective for the early detection of COPD.  
The purpose of this study was to identify which type of examination among “Ningen 
Dock” examinations, regularly-scheduled check-ups, screening in outpatient clinics and 
COPD screening is the most useful screening method for the early detection of COPD. 
 
Materials and Methods 
Subjects 
  For the “Ningen Dock” examinations, regularly-scheduled check-ups and screening 
in outpatient clinics, a retrospective epidemiological survey was performed in 4,135 
subjects who attended one of 17 hospitals in Saitama, Ibaraki, Shiga, Kyoto, Osaka, 
Kagoshima or Okinawa between February and March of 2008. 
  For COPD screening, 795 subjects (488 men, 307 women) among the residents of 
one city and one town in Nagasaki Prefecture who were 50 years of age or older with a 
score of at least 5 points on the 11-Q, were enrolled during 2006 and 2007. 
  A diagnosis of airflow limitation was made when the forced expiratory volume in one 
second (FEV1)/forced vital capacity (FVC) ratio was 70% or less. The staging of the 
disease was divided into stages I to IV based on the GOLD criteria (2). 
 
Definitions of the examinations 
  “Ningen Dock”: This is a voluntary health examination in which many tests are 
 6 
 
conducted with the aim of achieving early detection and early treatment of disease in 
addition to disease prevention. 
  Regularly-scheduled checkup: This is a compulsory health examination for all 
employees and is required by the Industrial Safety and Health Law. An annual 
examination is obligatory. 
  Screening in outpatient clinics: This screening method utilizes pulmonary function 
testing in patients who have not been diagnosed with respiratory disease and who are 
attending hospital outpatient clinics for the management of other chronic conditions. 
  COPD screening: This is a test protocol that determines those at risk for COPD by 
conducting pulmonary function testing in individuals who score 5 points or more on the 
11-Q completed by all residents 50 years of age or older in a specified region. 
 
Measurements 
  The 11-Q was used for COPD screening. It consists of 11 items, including smoking 
status, age, cough, phlegm and shortness of breath. A score of 5 points was used as the 
cutoff value, and people scoring 5 points or more were identified as subjects for COPD 
screening (13). 
  Age and smoking status were ascertained by questioning. Smoking status was defined 
according to the Brinkman Index (BI) divided into seven classes (BI less than 200 
(score 0), BI 200–400 (score 1), BI 401–600 (score 2), BI 601–800 (score 3), BI 801–
1,000 (score 4), BI 1,001–1,200 (score 5), BI 1,201–1,600 (score 6), BI over 1,601 
(score 7)) and smoking history (lifetime nonsmoker, current smoker, ex-smoker). The 
FEV1 and FVC were measured and used to calculate the FEV1/FVC ratio. Spirometry 
was conducted by clinical technologists and physiotherapists in the screening facilities 
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using equipment that satisfied the medical equipment standard of the Japanese 
Respiratory Society. The best of three technically correct maneuvers was taken as the 
measured value. Reversibility testing with inhaled bronchodilators was not performed 
due to the screening. 
 
Statistics 
  Comparisons of age, FVC, FEV1 and the FEV1/FVC ratio in each type of 
examination were made using one-way analyses of variance followed by Scheffe’s 
post-hoc tests. The Kruskal-Wallis test was performed to investigate differences in 
smoking status. The chi-square test was performed to investigate differences in GOLD 
stage with respect to the four types of examinations. 
  The ratio of subjects with airflow limitation determined according to age and all 
medical examinations was used to calculate the prevalence of airflow limitation. A 
multivariate logistic regression analysis was conducted with the presence of airflow 
limitation as the dependent variable and the type of screening (“Ningen Dock”, 
regularly-scheduled check-up, screening in outpatient clinics, COPD screening) as well 
as age as the explanatory variables. The odds ratio of airflow limitation for each type of 
examination was obtained with “Ningen Dock” as the reference, when corrected by sex, 
age and smoking status. 
  The analyses were performed separately for men and women. A probability (p) value 
of < 0.05 was considered to be significant. 
 
Results 
  A flow-chart of the study subjects who underwent “Ningen Dock” examinations, 
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regularly-scheduled checkups and screening in outpatient clinics is shown in Figure 1. 
Ultimately, 2,572 subjects (1,581 men, 991 women) were deemed eligible for this study. 
The gender distribution was as follows: 941 subjects (721 men, 220 women) in the 
“Ningen Dock” group, 1,457 subjects (769 men, 688 women) in the regularly-scheduled 
checkup group and 174 subjects (91 men, 83 women) in the screening in outpatient 
clinics group. 
  A flow-chart of the study subjects who underwent COPD screening using the 11-Q is 
shown in Figure 2. Regarding COPD screening, the total number of subjects over 50 
years of age was 12,013. Of the 6,136 subjects who responded to the 11-Q, the numbers 
of subjects who scored less than 5 points on the 11-Q or had missing data were 3,830 
and 12, respectively. Of the 2,294 subjects with an 11-Q score of 5 points or more, 804 
underwent COPD screening. Ultimately, 795 subjects (488 men, 307 women) were 
deemed eligible, excluding one person of age unknown and eight people who did not 
perform spirometry (Figure 2). 
  Table 1 shows the characteristics of the subjects. The percentages of men and women 
over 60 years of age for the four types of examinations were 35.8% and 21.8% in the 
“Ningen Dock” group, 55% and 49.7% in the regularly-scheduled checkup group, 
67.1% and 68.6% in the screening in outpatient clinics group and 72.6% and 76.9% in 
the COPD screening group, respectively. 
  Table 2 shows the smoking status and smoking history according to the type of 
examination. The COPD screening group exhibited the highest smoking status among 
men. The “Ningen Dock” group contained the highest number of current smokers (men: 
83.4%, women: 43.2%). Among men, the “Ningen Dock” group had the highest ratio of 
people with a smoking history, including smokers and former smokers at 90.8%, 
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followed by the COPD screening group at 82.3%, the screening in outpatient clinics 
group at 81.3% and the regularly-scheduled checkup group at 69.1%. The proportion of 
men smokers (current or former) was significantly higher than that of women smokers 
in all types of examinations (the gender ratios of the subjects were as follows: “Ningen 
Dock”: 90.8%/46.4%, regularly-scheduled checkup: 69.1%/19.2%, screening in 
outpatient clinics: 81.3%/21.7%, COPD screening: 82.3%/15.0%, p<0.0001).  
  Table 3 shows the prevalence of airflow limitation and the odds ratios for airflow 
limitation according to the type of examination. The COPD screening group had the 
highest prevalence of airflow limitation among men at 31.1%. Furthermore, the 
prevalence of airflow limitation increased in association with age in men. The COPD 
screening group had the highest odds ratio for airflow limitation in men (OR: 2.469; 
95% CI: 1.714 – 3.555). The odds ratios for the ages of the men and women were 1.090 
(CI: 1.072 – 1.108) and 1.057 (CI: 1.028 -1.088), respectively, and the odds ratio for the 
smoking status of men was 1.163 (CI: 1.091 – 1.240). Among women, no statistical 
significance regarding the odds ratios for COPD was observed in items other than age. 
 According to the COPD severity determined based on the GOLD stage, the percentage 
of stage I-II subjects tended to be higher than the percentage of stage III-IV subjects in 
the COPD screening group for men (Table 4). 
 
Discussion 
  The present study showed that detection of any airflow limitations using both the 
11-Q and pulmonary function tests is the most useful type of COPD screening in 
patients 50 years of age or older. Even after the detection rate was corrected for sex, age 
and smoking habits, the method using both the 11-Q and pulmonary function testing had 
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a higher probability of successfully screening for airflow limitations compared with the 
other types of examinations. COPD screening was especially useful in elderly people 
and people with a high smoking status. Indeed, the number of people 60 years or older 
accounted for over 70% of all subjects in the COPD screening group (men: 72.6%, 
women: 76.9%). This study indicated that the prevalence of COPD is highest among 
people in their sixties, seventies and eighties, consistent with the fact that the prevalence 
of COPD increases with age (6, 14, 15). 
   The men in the COPD screening group exhibited the highest prevalence of COPD 
among the four groups. These subjects also had a high risk for COPD caused by 
smoking. Miravitlles et al. and Zhone et al. (14, 15) reported that the prevalence of 
COPD is high among people with a high smoking index. In the present study, the 
smoking status was associated with detection of airflow limitation. Although the 
smoking history in the Ningen Dock group was the highest among the four groups, the 
prevalence of airflow limitation was low in both men and women. It may be that the 
subjects in this group were younger than those in the other groups. Conversely, many 
elderly subjects with a smoking history were included in the COPD screening group, 
thus resulting in a higher rate of detection of airflow limitation. Therefore, the rate of 
detection of airflow limitation may be associated with age and smoking status rather 
than smoking history. 
That the percentage of people with GOLD stage I-II disease tended to be higher than 
the percentage of people with stage III-IV disease in the COPD screening of men 
indicates that COPD screening may contribute to the early detection of COPD.  
  We identified the advantages and disadvantages of each of the four types of 
examinations. The “Ningen Dock” examination is a common type of examination for 
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people in their fifties in Japan, although it is optional. However, because the rate of 
smoking was high among subjects completing the regularly-scheduled checkups, this 
examination may be effective in detecting people at risk for COPD. Annual screening is 
obligatory during regularly-scheduled checkups; therefore, continuous screening of 
individuals is possible. Screening in outpatient clinics is limited to people with 
symptoms and/or underlying diseases. However, since COPD is a major comorbidity in 
subjects with underlying diseases, screening in outpatient clinics may be effective for 
identifying COPD. It is important to realize that COPD can be detected with any 
screening method when clinicians are aware of the high prevalence of the disease. We 
considered that COPD screening involving a questionnaire that includes the two items 
of smoking and respiratory distress as risk factors for COPD may effectively detect 
latent COPD. Reversibility tests with bronchodilators were not performed in this study. 
Therefore, subjects with an FEV1/FVC ratio < 70% in the screening may have included 
those with diseases other than COPD that are characterized by airflow limitation. 
  COPD screening does not lead to a definitive diagnosis of COPD; however, it is 
important to identify people at risk for COPD among a wide range of community 
residents and to encourage such persons to consult specialists in pulmonary medicine. 
Although COPD screening requires time and expense, it can detect people at risk for 
COPD and lead to early diagnoses. Early diagnosis promotes early intervention before 
the burden of COPD on society becomes significant. Therefore, COPD screening may 
ultimately help to reduce the burden of COPD on society. 
  We conclude that the COPD screening examination is an effective method leading to 
the early diagnosis of COPD. Furthermore, the 11-Q can serve as a first screening to 
identify people at risk for COPD among a wide range of community residents. 
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  A limitation associated with the present study is the presence of some selection bias 
because the subjects were not randomly selected. Additionally, reversibility testing was 
not conducted, which may have led to an overestimation of the prevalence of airflow 
limitation due to COPD. With respect to women, the number of subjects receiving any 
form of examination was small. Therefore, no statistical significance was observed in 
the odds ratios for airflow limitation for variables other than age. 
 
Conclusion 
  When comparing the prevalence of airflow limitation in subjects undergoing various 
types of examinations in this study, we found that the prevalence of COPD was highest 
in the COPD screening examinations. COPD screening, which incorporates the use of 
the 11-Q questionnaire, may selectively identify people at risk for COPD by providing 
questionnaires to a wide range of community residents and recruiting them as subjects 
for additional screening with pulmonary function testing. Accordingly, COPD screening 
is a type of examination that may be effectively used for the early detection of COPD. 
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Figure 1. Flow-chart of the study subjects who underwent Ningen Dock examinations, 




Subjects who underwent Ningen Dock examinations, 
regularly-scheduled checkups, and screenings in outpatient clinics 
n = 4,135 
Age < 50  
n = 1,438 
Subjects did not perform spirometry 
n = 121 
Poor spirometry maneuver 
n = 4 
Age ≥ 50 
n = 2,697 
Subjects who performed spirometry 
n = 2,576 
Eligible subjects 
n = 2,572 
 
 
Ningen Dock  
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Figure 2. Flow-chart of the study subjects in the COPD screening using the 11-Q. 
Subjects living in the two communities in Nagasaki prefecture 
and aged over 50 years 
n =12,013 
Subjects who responded to 11-Q 
n=6,136 
n = 6136 
Subjects who did not respond to 11-Q  
n =5,877 
 
11-Q ≥ 5 points 
n = 2,294 
11-Q < 5 points n = 3,830 
11-Q missing value n = 12 
Subjects who underwent COPD screening 
n = 804 
Poor spirometry maneuver n = 8 
Age unknown n = 1 
Eligible subjects 




Table 1. Characteristics of the subjects 
Ningen Dock Regularly-scheduledcheckup
Screening in
outpatient clinics COPD screening Total
Men 721 769 91 488 2,069
Age Mean(SD) 58.7±7.0*** 60.9±8.9***,† 60.7±9.0*** 66.1±8.5 61.3±8.6
  50-59 n(%) 463(64.2) 346(45.0) 30(33.0) 134(27.5) 973(46.0)
  60-69 n(%) 181(25.1) 270(35.1) 27(29.7) 156(32.0) 634(30.6)
  70-79 n(%) 72(10.0) 125(16.3) 33(36.3) 177(36.3) 407(19.7)
   ≥80 n(%) 5(0.7) 28(3.6) 1(1.1) 21(4.3) 55(2.7)
   ≥60 n(%) 258(35.8) 423(55.0) 61(67.1) 354(72.6) 1096(53.0)
FVC (l） 3.51±0.65*** 3.24±0.7*,† 3.17±0.78† 3.13±0.73 3.30±0.71
FEV1 (l） 2.80±0.59*** 2.65±0.6***,† 2.55±0.75**,‡ 2.30±0.68 2.61±0.65
FEV1/FVC (%) 79.7±7.5*** 81.9±8.8***,† 80.1±12.4*** 72.7±11.6 78.9±10.0
Women 220 688 83 307 1,298
Age Mean(SD) 56.3±5.3*** 60.3±9.5***,† 60.2±8.4***,‡ 66.5±8.0 61.1±9.2
  50-59 n(%) 172(78.2) 346(50.3) 26(31.3) 71(23.1) 615(47.4)
  60-69 n(%) 42(19.1) 203(29.5) 31(37.3) 108(35.2) 384(29.6)
  70-79 n(%) 6(2.7) 109(15.8) 24(28.9) 121(39.4) 260(20.0)
   ≥80 n(%) 0(0.0) 30(4.4) 2(2.4) 7(2.3) 39(3.0)
   ≥60 n(%) 48(21.8) 342(49.7) 57(68.6) 236(76.9) 683(52.6)
FVC (l） 2.64±0.48*** 2.30±0.52***,† 2.41±0.59***,‡ 2.13±0.53 2.32±0.55
FEV1 (l） 2.19±0.41*** 1.91±0.45***,† 1.93±0.47**,† 1.70±0.44 1.91±0.47




Data are mean (SD) or number (%) of subjects. 
FEV1: forced expiratory volume in one second  
FVC: forced vital capacity 
*** p<0.0001, ** p<0.01, * p<0.05 in comparisons versus COPD screening 
†p<0.0001, ‡ p<0.01, §p<0.05 in comparisons versus Ningen Dock  
¶ p<0.01 in comparisons versus regularly-scheduled checkup 
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Table 2. Smoking status and smoking history of the subjects 
Ningen Dock Regularly-scheduledcheckup
Screening in
outpatient clinics COPD screening Total
Men Smoking status 2.04±1.81*** 1.97±2.15*** 2.66±0.91**¶ 3.48±2.13 2.38±2.13
Smoking history Never smoker 67(9.3) 238(30.9) 17(18.7) 36(7.4) 358(17.3)
Current smoker 601(83.4) 516(67.1) 67(73.6) 252(51.6) 1,436(69.4)
Former smoker 53(7.4) 15(2.0) 7(7.7) 150(30.7) 225(10.9)
Unknown 0(0) 0(0) 0(0) 50(10.2) 50(2.4)
Women Smoking status 0.38±0.86† 0.24±0.82 0.31±0.91 0.39±1.13 0.31±0.92
Smoking history Never smoker 118(53.6) 556(80.8) 65(78.3) 231(75.2) 970(74.7)
Current smoker 95(43.2) 130(18.9) 17(20.5) 34(11.1) 276(21.3)
Former smoker 7(3.2) 2(0.3) 1(1.2) 12(3.9) 22(1.7)
Unknown 0(0) 0(0) 0(0) 30(9.8) 30(2.3)  
Data of smoking status are mean ± SD and data of smoking history are numbers (%) of subjects grouped according to smoking status for the four types of 
examination (Ningen Dock, regularly-scheduled checkup, Screening in outpatient clinics, and COPD screening). 
Smoking status: BI less than 200 (score 0), BI 200–400 (score 1), BI 401–600 (score 2), BI 601–800 (score 3), BI 801–1000 (score 4), 
BI 1001–1200 (score 5), BI 1201–1600 (score 6), BI over 1601 (score 7)  
“Unknown” indicates number of the subjects who did not provide data on smoking status. 
*** p<0.0001, ** p<0.01 in comparisons versus COPD screening 
†p<0.0001, ¶ p<0.01 in comparisons versus regularly-scheduled checkup 
 19 
 













 interval p value
Men Ningen Dock 664 57 7.9 1.000 　reference 　－
Regularly-scheduled checkup 712 57 7.4 0.701 0.470 - 1.046 0.082
Screening in outpatient clinics 80 11 12.1 1.132 0.552 - 2.324 0.735
COPD screening 336 152 31.1 2.469 1.714 - 3.555 ＜0.0001
Smoking Status 　－ 　－ 　－ 1.163 1.091 - 1.240 ＜0.0001
Age 　－ 　－ 　－ 1.090 1.072 - 1.108 ＜0.0001
  50-59 921 52 5.3 　－ 　－ 　－
  60-69 549 85 13.4 　－ 　－ 　－
  70-79 286 121 29.7 　－ 　－ 　－
  ≥80 36 19 34.5 　－ 　－ 　－
Women Ningen Dock 216 4 1.8 1.000 　reference －
Regularly-scheduled checkup 660 28 4.1 1.673 0.567 - 4.940 0.351
Screening in outpatient clinics 77 6 7.2 3.233 0.876 - 11.933 0.078
COPD screening 282 25 8.1 2.611 0.853 - 7.995 0.093
Smoking Status － － － 1.055 0.821 - 1.356 0.674
Age － － － 1.057 1.028 - 1.088 ＜0.0001
  50-59 599 16 2.6 　－ 　－ 　－
  60-69 369 15 3.9 　－ 　－ 　－
  70-79 231 29 11.2 　－ 　－ 　－
  ≥80 36 3 7.7 　－ 　－ 　－  
Men (χ2=175.238, df=3, p<0.0001), Women  (χ2=13.513, df=3, p=0.004) in four types of examination 




Table 4. Spirometric classification of COPD severity  
Ningen Dock Regularly-scheduledcheckup
Screening in
outpatient clinics COPD screening Total
Men n 721 769 91 488 2,069
Stage I-II 47(6.5) 49(6.4) 6(6.6) 113(23.2) 215(10.4)
Stage III-IV 10(1.4) 8(1.0) 5(5.5) 39(8.0) 62(3.0)
Women n 220 688 83 307 1,298
Stage I-II 2(0.9) 5(0.7) 3(3.6) 8(2.6) 18(1.4)
Stage III-IV 2(0.9) 23(3.3) 3(3.6) 17(5.5) 45(3.5)
Data are number (%) of Spirometric Classification of COPD Severity for the four types of examination (Ningen Dock, Regularly-scheduled checkup, 
screening in outpatient clinics, and COPD screening) 
Stage.I: FEV1 ≥ 80% predicted 
  Stage II: 50% ≤ FEV1 < 80% predicted 
Stage III: 30% ≤ FEV1 < 50% predicted 
  Stage IV: FEV1 < 30% predicted 
Men (χ2=7.363, df=3, p=0.061), Women (χ2=3.969, df=3, p=0.265) 
 
 
